Neoplastic Disorders of Bone Marrow

Section IV - Neoplastic Disorders of Bone Marrow

Published online by Cambridge University Press: 25 January 2024

Edited by

Xiayuan Liang ,

Bradford Siegele and

Jennifer Picarsic

Show author details

Xiayuan Liang: Affiliation:
Children’s Hospital of Colorado
Bradford Siegele: Affiliation:
Children’s Hospital of Colorado
Jennifer Picarsic: Affiliation:
Cincinnati Childrens Hospital Medicine Center

Book contents

Get access

Type: Chapter
Information: Pediatric Pathology of Hematopoietic and Histiocytic Disorders , pp. 97 - 234

DOI: https://doi.org/10.1017/9781009105002 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Swerdlow, S, Campo, E, Harris, N, et al., eds. WHO classification of tumors of haematopoietic and lymphoid tissues. Rev. 4th ed. Lyon, France: IARC Press; 2017.Google Scholar

Wood, B, Wu, D, Crossley, B, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018;131:1350–9.Google Scholar

Borowitz, MJ, Wood, BL, Devidas, M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood. 2015;126:964–71.Google Scholar

Wood, BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 2016;90:47–53.Google Scholar

Berry, DA, Zhou, S, Higley, H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.Google Scholar

Brown, PA, Wieduwilt, M, Logan, A, et al. Guidelines insights: acute lymphoblastic leukemia, version 1.2019. J Natl Compr Canc Netw. 2019;17:414–23.Google Scholar

Theunissen, P, Mejstrikova, E, Sedek, L, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129:347–57.Google Scholar

Brando, B, Gatti, A, Preijers, F. Flow cytometric diagnosis of paroxysmal nocturnal hemoglobinuria: pearls and pitfalls – a critical review article. EJIFCC. 2019;30:355–70.Google Scholar

Illingworth, A, Marinov, I, Sutherland, DR, et al. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 3-data analysis, reporting and case studies. Cytometry B Clin Cytom. 2018;94:49–66.Google Scholar

Fisher, GH, Rosenberg, FJ, Straus, SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 1995;81:935–46.Google Scholar

Oliveira, JB, Bleesing, JJ, Dianzani, U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116:e35–40.Google Scholar

Chisholm, KM, Xu, M, Davis, B, et al. Evaluation of the utility of bone marrow morphology and ancillary studies in pediatric patients under surveillance for myelodysplastic syndrome. Am J Clin Pathol. 2018;149:499–513.Google Scholar

Veltroni, M, Sainati, L, Zecca, M, et al. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool? Pediatr Blood Cancer. 2009;52:357–63.Google Scholar

Pittaluga, S, Barry, TS, Raffeld, M. Immunohistochemistry for the hematopathology laboratory. In: Jaffe, ES, Arber, DA, Campo, E, et al., eds. Hematopathology. 2nd ed. Philadelphia, PA: Elsevier; 2017:41–52.Google Scholar

Taylor, CR, Rudbeck, L. Immunohistochemical staining methods. 6th ed. Glostrup, Denmark: Dako Denmark; 2013.Google Scholar

Heim, S, Mitelman, F. Primary chromosome abnormalities in human neoplasia. Adv Cancer Res. 1989;52:1–43.Google Scholar

Dohner, H, Estey, E, Grimwade, D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.Google Scholar

Hunger, SP, Mullighan, CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125:3977–87.Google Scholar

Vujkovic, M, Attiyeh, EF, Ries, RE, et al. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children’s Oncology Group report. Blood. 2017;129:3051–8.Google Scholar

Greenberg, PL, Tuechler, H, Schanz, J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.Google Scholar

Dou, H, Chen, X, Huang, Y, et al. Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2017;56:135–46.Google Scholar

Lange, BJ, Kobrinsky, N, Barnard, DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children’s Cancer Group Studies 2861 and 2891. Blood. 1998;91:608–15.Google Scholar

Choi, SE, Hong, SW, Yoon, SO. Proposal of an appropriate decalcification method of bone marrow biopsy specimens in the era of expanding genetic molecular study. J Pathol Transl Med. 2015;49:236–42.Google Scholar

Al Hinai, ASA, Grob, T, Kavelaars, FG, et al. Archived bone marrow smears are an excellent source for NGS-based mutation detection in acute myeloid leukemia. Leukemia. 2020;34:2220–4.Google Scholar

Czuchlewski, DR, Peterson, LC. Myeloid neoplasms with germline predisposition: a new provisional entity within the World Health Organization classification. Surg Pathol Clin. 2016;9:165–76.Google Scholar

Chaudhary, G, Dogra, TD, Raina, A. Evaluation of blood, buccal swabs, and hair follicles for DNA profiling technique using STR markers. Croat Med J. 2015;56:239–45.Google Scholar

Preuner, S, Danzer, M, Pröll, J, et al. High-quality DNA from fingernails for genetic analysis. J Mol Diagn. 2014;16:459–66.Google Scholar

Murphy, KM, Levis, M, Hafez, MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5(2):96–102.Google Scholar

`National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: acute myeloid leukemia. Version 3. 2021.Google Scholar

`Tozzo, P, Delicati, A, Zambello, R, et al. Chimerism monitoring techniques after hematopoietic stem cell transplantation: an overview of the last 15 years of innovations. Diagnostics (Basel). 2021;11:621.Google Scholar

Sanger, F, Nicklen, S, Coulson, AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977;74:5463–7.Google Scholar

Liu, W, Saint, DA. A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. Anal Biochem. 2002;302:52–9.Google Scholar

Schuurhuis, GJ, Heuser, M, Freeman, S, et al. Minimal/measurable residual disease in AML: a consensus document from the European Leukemia Net MRD Working Party. Blood. 2018;131:1275–91.Google Scholar

Hughes, T, Deininger, M, Hochhaus, A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37.Google Scholar

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 3. 2020.Google Scholar

Bentley, DR, Balasubramanian, S, Swerdlow, HP, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008;456:53–9.Google Scholar

Zheng, Z, Liebers, M, Zhelyazkova, B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20:1479–84.Google Scholar

van Dongen, JJ, Langerak, AW, Brüggemann, M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317.Google Scholar

van der Velden, VH, van Dongen, JJ. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol. 2009;538:115–50.Google Scholar

Mahe, E, Pugh, T, Kamel-Reid, S. T cell clonality assessment: past, present and future. J Clin Pathol. 2018;71:195–200.Google Scholar

Medina, A, Puig, N, Flores-Montero, J, et al. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J. 2020;10:108.Google Scholar

Schmitt, MW, Kennedy, SR, Salk, JJ, et al. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci USA. 2012;109:14508–13.Google Scholar

Yoest, JM, Shirai, CL, Duncavage, EJ. Sequencing-based measurable residual disease testing in acute myeloid leukemia. Front Cell Dev Biol. 2020;8:249.Google Scholar

Quan, PL, Sauzade, M, Brouzes, E. dPCR: a technology review. Sensors (Basel). 2018;18:1271.Google Scholar

Pettersson, L, Alm, JS, Almstedt, A, et al. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia. Int J Lab Hematol. 2021;43:664–74.Google Scholar

References

Swerdlow, S, Campo, E, Harris, N, et al., eds. WHO classification of tumors of haematopoietic and lymphoid tissues. Rev. 4th ed. Lyon, France: IARC Press; 2017.Google Scholar

Chan, RJ, Cooper, T, Kratz, CP, et al. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res. 2009;33(3):355–62. doi: 10.1016/j.leukres.2008.08.022 Google Scholar

Loh, ML, Sakai, DS, Flotho, C, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009;114(9):1859–63. doi: 10.1182/blood-2009-01-198416 Google Scholar

Niemeyer, CM, Arico, M, Basso, G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997;89(10):3534–43.Google Scholar

Luna-Fineman, S, Shannon, KM, Atwater, SK, et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood. 1999;93(2):459–66.Google Scholar

Gupta, AK, Meena, JP, Chopra, A, et al. Juvenile myelomonocytic leukemia – a comprehensive review and recent advances in management. Am J Blood Res. 2021;11(1):1–21.Google Scholar

Aricò, M, Biondi, A, Pui, CH. Juvenile myelomonocytic leukemia. Blood. 1997;90(2):479–88.Google Scholar

Aalbers, AM, van den Heuvel-Eibrink, MM, de Haas, V, et al. Applicability of a reproducible flow cytometry scoring system in the diagnosis of refractory cytopenia of childhood. Leukemia. 2013;27(9):1923–5. doi: 10.1038/leu.2013.81 Google Scholar

Emanuel, PD, Bates, LJ, Zhu, SW, et al. The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. Exp Hematol. 1991;19(10):1017–24.Google Scholar

Loh, ML, Vattikuti, S, Schubbert, S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004;103(6):2325–31. doi: 10.1182/blood-2003-09-3287 Google Scholar

Stieglitz, E, Taylor-Weiner, AN, Chang, TY, et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015;47(11):1326–33. doi: 10.1038/ng.3400 Google Scholar

Niemeyer, CM, Kang, MW, Shin, DH, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010;42(9):794–800. doi: 10.1038/ng.641 Google Scholar

Tartaglia, M, Mehler, EL, Goldberg, R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29(4):465–8. doi: 10.1038/ng772 Google Scholar

Tartaglia, M, Pennacchio, LA, Zhao, C, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet. 2007;39(1):75–9. doi: 10.1038/ng1939 Google Scholar

Schubbert, S, Zenker, M, Rowe, SL, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet. Mar 2006;38(3):331–6. doi: 10.1038/ng1748 Google Scholar

Pandit, B, Sarkozy, A, Pennacchio, LA, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39(8):1007–12. doi: 10.1038/ng2073 Google Scholar

Caye, A, Strullu, M, Guidez, F, et al. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nat Genet. 2015;47(11):1334–40. doi: 10.1038/ng.3420 Google Scholar

Sakaguchi, H, Okuno, Y, Muramatsu, H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 2013;45(8):937–41. doi: 10.1038/ng.2698 Google Scholar

Nucera, S, Fazio, G, Piazza, R, et al. Germ-line TP53 mutation in an adolescent with CMML/atypical CML and familiar cancer predisposition. Hemasphere. 2020;4(5):e460. doi: 10.1097/HS9.0000000000000460 Google Scholar

Patnaik, MM, Tefferi, A. Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(1):97–115. doi: 10.1002/ajh.25684 Google Scholar

Federmann, B, Abele, M, Rosero Cuesta, DS, et al. The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia. Hum Pathol. 2014;45(12):2471–9. doi: 10.1016/j.humpath.2014.08.014 Google Scholar

Meggendorfer, M, Roller, A, Haferlach, T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012;120(15):3080–8. doi: 10.1182/blood-2012-01-404863 Google Scholar

Patnaik, MM, Itzykson, R, Lasho, TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28(11):2206–12. doi: 10.1038/leu.2014.125 Google Scholar

Breccia, M, Biondo, F, Latagliata, R, et al. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 2006;91(11):1566–8.Google Scholar

Wang, SA, Hasserjian, RP, Fox, PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014;123(17):2645–51. doi: 10.1182/blood-2014-02-553800 Google Scholar

Melo, JV, Myint, H, Galton, DA, et al. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia. 1994;8(1):208–11.Google Scholar

Borkhardt, A, Bojesen, S, Haas, OA, et al. The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci USA. 2000;97(16):9168–73. doi: 10.1073/pnas.150079597 Google Scholar

Janik-Moszant, A, Barć-Czarnecka, M, van der Burg, M, et al. Concomitant EBV-related B-cell proliferation and juvenile myelomonocytic leukemia in a 2-year-old child. Leuk Res. Jan 2008;32(1):181–4. doi: 10.1016/j.leukres.2007.05.017 Google Scholar

Lorenzana, A, Lyons, H, Sawaf, H, et al. Human herpesvirus 6 infection mimicking juvenile myelomonocytic leukemia in an infant. J Pediatr Hematol Oncol. 2002;24(2):136–41. doi: 10.1097/00043426-200202000-00016 Google Scholar

Strauss, A, Furlan, I, Steinmann, S, et al. Unmistakable morphology? Infantile malignant osteopetrosis resembling juvenile myelomonocytic leukemia in infants. J Pediatr. 2015;167(2):486–8. doi: 10.1016/j.jpeds.2015.04.064 Google Scholar

References

Swerdlow, S, Campo, E, Harris, N, et al., eds. WHO classification of tumors of haematopoietic and lymphoid tissues. Rev. 4th ed. IARC Press; 2017.Google Scholar

Klion, AD, Robyn, J, Akin, C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103(2):473–8. doi: 10.1182/blood-2003-08-2798 Google Scholar

Dalal, BI, Horsman, DE, Bruyèrè, H, et al. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation. Am J Hematol. 2007;82(1):77–9. doi: 10.1002/ajh.20833 Google Scholar

Bain, BJ, Fletcher, SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am. 2007;27(3):377–88. doi: 10.1016/j.iac.2007.06.001 Google Scholar

Vandenberghe, P, Wlodarska, I, Michaux, L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18(4):734–42. doi: 10.1038/sj.leu.2403313 Google Scholar

Naymagon, L, Marcellino, B, Mascarenhas, J. Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. Blood Rev. 2019;36:23–31. doi: 10.1016/j.blre.2019.03.007 Google Scholar

Fournier, B, Balducci, E, Duployez, N, et al. B-ALL with t(5;14)(q31;q32). Front Oncol. 2019;9:1374. doi: 10.3389/fonc.2019.01374 Google Scholar

Klion, AD, Law, MA, Riemenschneider, W, et al. Familial eosinophilia: a benign disorder? Blood. 2004;103(11):4050–5. doi: 10.1182/blood-2003-11-3850 Google Scholar

Reiter, A, Gotlib, J. Myeloid neoplasms with eosinophilia. Blood. 2017;129(6):704–714. doi: 10.1182/blood-2016-10-695973 Google Scholar

Rumi, E, Milosevic, JD, Selleslag, D, et al. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann Hematol. 2015;94(11):1927–8. doi: 10.1007/s00277-015-2451-7 Google Scholar

Lierman, E, Selleslag, D, Smits, S, et al. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood. 2012;120(7):1529–31. doi: 10.1182/blood-2012-06-433821 Google Scholar

References

Swerdlow, S, Campo, E, Harris, N, et al., eds. WHO classification of tumors of haematopoietic and lymphoid tissues. Rev. 4th ed. IARC Press; 2017.Google Scholar

Höglund, M, Sandin, F, Simonsson, B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94 Suppl 2:S241–7. doi: 10.1007/s00277-015-2314-2 Google Scholar

Bleyer, A, Viny, A, Barr, R. Cancer in 15- to 29-year-olds by primary site. Oncologist. 2006;11(6):590–601. doi: 10.1634/theoncologist.11-6-590 Google Scholar

Krumbholz, M, Karl, M, Tauer, JT, et al. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosomes Cancer. 2012;51(11):1045–53. doi: 10.1002/gcc.21989 Google Scholar

Millot, F, Traore, P, Guilhot, J, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005;116(1):140–3. doi: 10.1542/peds.2004-2473 Google Scholar

Berger, U, Maywald, O, Pfirrmann, M, et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005;19(6):984–9. doi: 10.1038/sj.leu.2403756 Google Scholar

Landgren, O, Goldin, LR, Kristinsson, SY, et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112(6):2199–204. doi: 10.1182/blood-2008-03-143602 Google Scholar

Hijiya, N, Millot, F, Suttorp, M. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions. Pediatr Clin North Am. 2015;62(1):107–19. doi: 10.1016/j.pcl.2014.09.008 Google Scholar

Millot, F, Maledon, N, Guilhot, J, et al. Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia. Eur J Cancer. 2019;115:17–23. doi: 10.1016/j.ejca.2019.03.020 Google Scholar

Cotta, CV, Bueso-Ramos, CE. New insights into the pathobiology and treatment of chronic myelogenous leukemia. Ann Diagn Pathol. 2007;11(1):68–78. doi: 10.1016/j.anndiagpath.2006.12.002 Google Scholar

Czader, M, Orazi, A. Acute myeloid leukemia and other types of disease progression in myeloproliferative neoplasms. Am J Clin Pathol. 2015;144(2):188–206. doi: 10.1309/AJCPZQK40JOZZZCC Google Scholar

Hijiya, N, Schultz, KR, Metzler, M, et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127(4):392–9. doi: 10.1182/blood-2015-06-648667 Google Scholar

Athale, U, Hijiya, N, Patterson, BC, et al. Management of chronic myeloid leukemia in children and adolescents: recommendations from the Children’s Oncology Group CML Working Group. Pediatr Blood Cancer. 2019;66(9):e27827. doi: 10.1002/pbc.27827 Google Scholar

Thompson, PA, Kantarjian, HM, Cortes, JE. Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc. 2015;90(10):1440–54. doi: 10.1016/j.mayocp.2015.08.010 Google Scholar

Melo, JV, Myint, H, Galton, DA, et al. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia. 1994;8(1):208–11.Google Scholar

Koptyra, M, Falinski, R, Nowicki, MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 2006;108(1):319–27. doi: 10.1182/blood-2005-07-2815 Google Scholar

Skorski, T. Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer. 2002;2(5):351–60. doi: 10.1038/nrc799 Google Scholar

Nowicki, MO, Falinski, R, Koptyra, M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 2004;104(12):3746–53. doi: 10.1182/blood-2004-05-1941 Google Scholar

Soverini, S, Hochhaus, A, Nicolini, FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208–15. doi: 10.1182/blood-2010-12-326405 Google Scholar

Prokocimer, M, Rotter, V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood. 1994;84(8):2391–411.Google Scholar

Sill, H, Goldman, JM, Cross, NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood. Apr 15 1995;85(8):2013–6.Google Scholar

Grossmann, V, Kohlmann, A, Zenger, M, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3):557–60. doi: 10.1038/leu.2010.298 Google Scholar

Ernst, T, Busch, M, Rinke, J, et al. Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia. Leukemia. 2018;32(9):2046–2049. doi: 10.1038/s41375-018-0157-2 Google Scholar

Berger, R. Differences between blastic chronic myeloid leukemia and Ph-positive acute leukemia. Leuk Lymphoma. 1993;11 Suppl 1:235–7. doi: 10.3109/10428199309047892 Google Scholar

Uygun, V, Daloğlu, H, Öztürkmen, S, et al. Chronic neutrophilic leukemia, an extremely rare cause of neutrophilia in childhood: cure with hematopoietic stem cell transplantation. Pediatr Transplant. 2018;22(5):e13199. doi: 10.1111/petr.13199 Google Scholar

Böhm, J, Schaefer, HE. Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease. J Clin Pathol. 2002;55(11):862–4. doi: 10.1136/jcp.55.11.862 Google Scholar

Hehlmann, R. CML – where do we stand in 2015? Ann Hematol. 2015;94 Suppl 2:S103–5. doi: 10.1007/s00277-015-2331-1 Google Scholar

Hehlmann, R. How I treat CML blast crisis. Blood. 2012;120(4):737–47. doi: 10.1182/blood-2012-03-380147 Google Scholar

Osgood, EE. Polycythemia vera: age relationships and survival. Blood. 1965;26:243–56.Google Scholar

Cario, H, McMullin, MF, Pahl, HL. Clinical and hematological presentation of children and adolescents with polycythemia vera. Ann Hematol. 2009;88(8):713–9. doi: 10.1007/s00277-009-0758-y Google Scholar

Rumi, E. Familial chronic myeloproliferative disorders: the state of the art. Hematol Oncol. 2008;26(3):131–8. doi: 10.1002/hon.863 Google Scholar

Cario, H, Schwarz, K, Herter, JM, et al. Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera. Br J Haematol. 2008;142(4):622–6. doi: 10.1111/j.1365-2141.2008.07220.x Google Scholar

Najean, Y, Mugnier, P, Dresch, C, et al. Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years. Br J Haematol. 1987;67(3):285–91. doi: 10.1111/j.1365-2141.1987.tb02349.x Google Scholar

Heilmann, E, Klein, CE, Beck, JD. Primary polycythaemia in childhood and adolescence. Folia Haematol Int Mag Klin Morphol Blutforsch. 1983;110(6):935–41.Google Scholar

Barbui, T, Carobbio, A, Rambaldi, A, et al. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009;114(4):759–63. doi: 10.1182/blood-2009-02-206797 Google Scholar

Teofili, L, Giona, F, Martini, M, et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood. 2007;110(9):3384–6. doi: 10.1182/blood-2007-06-094276 Google Scholar

Tefferi, A. JAK2 mutations in polycythemia vera – molecular mechanisms and clinical applications. N Engl J Med. 2007;356(5):444–5. doi: 10.1056/NEJMp068293 Google Scholar

Andrieux, JL, Demory, JL. Karyotype and molecular cytogenetic studies in polycythemia vera. Curr Hematol Rep. 2005;4(3):224–9.Google Scholar

Adam, MP, Mirzaa, GM, Pagon, RA, et al. GeneReviews. University of Washington. 1993–2022.Google Scholar

Ladroue, C, Carcenac, R, Leporrier, M, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med. 2008;359(25):2685–92. doi: 10.1056/NEJMoa0806277 Google Scholar

Percy, MJ, Furlow, PW, Lucas, GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med. 2008;358(2):162–8. doi: 10.1056/NEJMoa073123 Google Scholar

Percy, MJ, Beer, PA, Campbell, G, et al. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood. 2008;111(11):5400–2. doi: 10.1182/blood-2008-02-137703 Google Scholar

Prchal, JT, Gregg, XT. Red cell enzymes. Hematology Am Soc Hematol Educ Program. 2005:19–23. doi: 10.1182/asheducation-2005.1.19 Google Scholar

Passamonti, F, Malabarba, L, Orlandi, E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003;88(1):13–8.Google Scholar

Marchioli, R, Finazzi, G, Landolfi, R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32. doi: 10.1200/JCO.2005.07.062 Google Scholar

Marchioli, R, Finazzi, G, Specchia, G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33. doi: 10.1056/NEJMoa1208500 Google Scholar

Passamonti, F, Rumi, E, Arcaini, L, et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer. 2005;104(5):1032–6. doi: 10.1002/cncr.21297 Google Scholar

Ianotto, JC, Curto-Garcia, N, Lauermanova, M, et al. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. Haematologica. 2019;104(8):1580–8. doi: 10.3324/haematol.2018.200832 Google Scholar

Hasle, H. Incidence of essential thrombocythaemia in children. Br J Haematol. 2000;110(3):751. doi: 10.1046/j.1365-2141.2000.02239-7.x Google Scholar

Giona, F, Teofili, L, Moleti, ML, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood. 2012;119(10):2219–27. doi: 10.1182/blood-2011-08-371328 Google Scholar

Hong, WJ, Gotlib, J. Hereditary erythrocytosis, thrombocytosis and neutrophilia. Best Pract Res Clin Haematol. 2014;27(2):95–106. doi: 10.1016/j.beha.2014.07.002 Google Scholar

Yang, RC, Qian, LS. Essential thrombocythaemia in children: a report of nine cases. Br J Haematol. 2000;110(4):1009–10. doi: 10.1046/j.1365-2141.2000.02270-7.x Google Scholar

Randi, ML, Putti, MC, Scapin, M, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood. 2006;108(10):3600–2. doi: 10.1182/blood-2006-04-014746 Google Scholar

Nakatani, T, Imamura, T, Ishida, H, et al. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia. Pediatr Blood Cancer. 2008;51(6):802–5. doi: 10.1002/pbc.21730 Google Scholar

Fu, R, Zhang, L, Yang, R. Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. Br J Haematol. Nov 2013;163(3):295–302. doi: 10.1111/bjh.12530 Google Scholar

Randi, ML, Putti, MC, Pacquola, E, et al. Normal thrombopoietin and its receptor (c-MPL) genes in children with essential thrombocythemia. Pediatr Blood Cancer. 2005;44(1):47–50. doi: 10.1002/pbc.20185 Google Scholar

Hofmann, I. Myeloproliferative neoplasms in children. J Hematop. 2015;8(3):143–157. doi: 10.1007/s12308-015-0256-1 Google Scholar

Wilkins, BS, Erber, WN, Bareford, D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111(1):60–70. doi: 10.1182/blood-2007-05-091850 Google Scholar

Tefferi, A, Barbui, T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 12 2020;95(12):1599–613. doi: 10.1002/ajh.26008 Google Scholar

Kucine, N. Myeloproliferative neoplasms in children, adolescents, and young adults. Curr Hematol Malig Rep. 2020;15(2):141–8. doi: 10.1007/s11899-020-00571-8 Google Scholar

Kucine, N, Viny, AD, Rampal, R, et al. Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation. Haematologica. 2016;101(6):e237–9. doi: 10.3324/haematol.2016.142935 Google Scholar

Kucine, N, Chastain, KM, Mahler, MB, et al. Primary thrombocytosis in children. Haematologica. 2014;99(4):620–8. doi: 10.3324/haematol.2013.092684 Google Scholar

Randi, ML, Geranio, G, Bertozzi, I, et al. Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort. Br J Haematol. 2015;169(4):584–9. doi: 10.1111/bjh.13329 Google Scholar

DeLario, MR, Sheehan, AM, Ataya, R, et al. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis – an entity different from adults. Am J Hematol. 2012;87(5):461–4. doi: 10.1002/ajh.23140 Google Scholar

Sheikha, A. Fatal familial infantile myelofibrosis. J Pediatr Hematol Oncol. 2004;26(3):164–8. doi: 10.1097/00043426-200403000-00005 Google Scholar

Sieff, CA, Malleson, P. Familial myelofibrosis. Arch Dis Child. 1980;55(11):888–93. doi: 10.1136/adc.55.11.888 Google Scholar

Dema, S, Lazar, F, Barna, R, et al. Sclerosing extramedullary hematopoietic tumor (SEHT) mimicking a malignant bile duct tumor – case report and literature review. Medicina (Kaunas). 2021;57(8):824. doi: 10.3390/medicina57080824 Google Scholar

Mishra, P, Halder, R, Aggarwal, M, et al. Pediatric myelofibrosis: WHO 2024 update on myeloproliferative neoplasms calling? Pediatr Blood Cancer. 2020;67(5):e28232. doi: 10.1002/pbc.28232 Google Scholar

An, W, Wan, Y, Guo, Y, et al. CALR mutation screening in pediatric primary myelofibrosis. Pediatr Blood Cancer. 2014;61(12):2256–62. doi: 10.1002/pbc.25211 Google Scholar

Stepensky, P, Saada, A, Cowan, M, et al. The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy. Blood. 2013;121(25):5078–87. doi: 10.1182/blood-2012-12-475566 Google Scholar

Vilboux, T, Lev, A, Malicdan, MC, et al. A congenital neutrophil defect syndrome associated with mutations in VPS45. N Engl J Med. Jul 04 2013;369(1):54–65. doi: 10.1056/NEJMoa1301296 Google Scholar

Altura, RA, Head, DR, Wang, WC. Long-term survival of infants with idiopathic myelofibrosis. Br J Haematol. 2000;109(2):459–62. doi: 10.1046/j.1365-2141.2000.01977.x Google Scholar

Sah, A, Minford, A, Parapia, LA. Spontaneous remission of juvenile idiopathic myelofibrosis. Br J Haematol. 2001;112(4):1083. doi: 10.1046/j.1365-2141.2001.02622.x Google Scholar

Lau, SO, Ramsay, NK, Smith, CM, et al. Spontaneous resolution of severe childhood myelofibrosis. J Pediatr. 1981;98(4):585–8. doi: 10.1016/s0022-3476(81)80769-x Google Scholar

Druhan, LJ, McMahon, DP, Steuerwald, N, et al. Chronic neutrophilic leukemia in a child with a CSF3R T618I germ line mutation. Blood. 2016;128(16):2097–9. doi: 10.1182/blood-2016-07-730606 Google Scholar

Elliott, MA, Hanson, CA, Dewald, GW, et al. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19(2):313–7. doi: 10.1038/sj.leu.2403562 Google Scholar

Plo, I, Zhang, Y, Le Couédic, JP, et al. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med. 2009;206(8):1701–7. doi: 10.1084/jem.20090693 Google Scholar

Duployez, N, Willekens, C, Plo, I, et al. Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. Blood. 2019;134(26):2414–6. doi: 10.1182/blood.2019003206 Google Scholar

Maxson, JE, Gotlib, J, Pollyea, DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781–90. doi: 10.1056/NEJMoa1214514 Google Scholar

References

Hasle, H, Niemeyer, CM, Chessells, JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2):277–82. doi: 10.1038/sj.leu.2402765 Google Scholar

Hasle, H, Niemeyer, CM. Advances in the prognostication and management of advanced MDS in children. Br J Haematol. 2011;154(2):185–95. doi: 10.1111/j.1365-2141.2011.08724.x Google Scholar

Kardos, G, Baumann, I, Passmore, SJ, et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood. 2003;102(6):1997–2003. doi: 10.1182/blood-2002-11-3444 Google Scholar

Swerdlow, S, Campo, E, Harris, N, et al., eds. WHO classification of tumors of haematopoietic and lymphoid tissues. Rev. 4th ed. IARC Press; 2017.Google Scholar

Rau, AT, Shreedhara, AK, Kumar, S. Myelodysplastic syndromes in children: where are we today? Ochsner J. 2012;12(3):216–20.Google Scholar

Polychronopoulou, S, Panagiotou, JP, Kossiva, L, et al. Clinical and morphological features of paediatric myelodysplastic syndromes: a review of 34 cases. Acta Paediatr. 2004;93(8):1015–23. doi: 10.1111/j.1651-2227.2004.tb02708.x Google Scholar

Hofmann, I. Pediatric myelodysplastic syndromes. J Hematopathology. 2015;8:127–41.Google Scholar

Fleming, MD. Congenital sideroblastic anemias: iron and heme lost in mitochondrial translation. Hematology Am Soc Hematol Educ Program. 2011;2011:525–31. doi: 10.1182/asheducation-2011.1.525 Google Scholar

Westers, TM, Ireland, R, Kern, W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26(7):1730–41. doi: 10.1038/leu.2012.30 Google Scholar

Ogata, K, Della Porta, MG, Malcovati, L, et al. Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. Haematologica. 2009;94(8):1066–74. doi: 10.3324/haematol.2009.008532 Google Scholar

Porwit, A, van de Loosdrecht, AA, Bettelheim, P, et al. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia. 2014;28(9):1793–8. doi: 10.1038/leu.2014.191 Google Scholar

Sperling, AS, Gibson, CJ, Ebert, BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17(1):5–19. doi: 10.1038/nrc.2016.112 Google Scholar

Nazha, A, Seastone, D, Radivoyevitch, T, et al. Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. Haematologica. 2015;100(11):e434–7. doi: 10.3324/haematol.2015.130112 Google Scholar

Schwartz, JR, Ma, J, Lamprecht, T, et al. The genomic landscape of pediatric myelodysplastic syndromes. Nat Commun. 2017;8(1):1557. doi: 10.1038/s41467-017-01590-5 Google Scholar

Pastor, V, Hirabayashi, S, Karow, A, et al. Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants. Leukemia. 2017;31(3):759–762. doi: 10.1038/leu.2016.342 Google Scholar

Hirabayashi, S, Flotho, C, Moetter, J, et al. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood. 2012;119(11):e96–9. doi: 10.1182/blood-2011-12-395087 Google Scholar

Mikhailova, N, Sessarego, M, Fugazza, G, et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica. 1996;81(5):418–22.Google Scholar

Dolan, MM, Singleton, TP, Neglia, J, et al. Aplastic anemia and monosomy 7-associated dysmegakaryocytopoiesis. Am J Clin Pathol. 2006;126(6):925–30. doi: 10.1309/50GWDKVWU3VWL5XW Google Scholar

Göhring, G, Michalova, K, Beverloo, HB, et al. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood. 2010;116(19):3766–9. doi: 10.1182/blood-2010-04-280313 Google Scholar

Woodard, P, Carpenter, PA, Davies, SM, et al. Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children. Biol Blood Marrow Transplant. 2011;17(5):723–8. doi: 10.1016/j.bbmt.2010.08.016 Google Scholar

Yusuf, U, Frangoul, HA, Gooley, TA, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant. 2004;33(8):805–14. doi: 10.1038/sj.bmt.1704438 Google Scholar

Bejar, R, Stevenson, K, Abdel-Wahab, O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496–506. doi: 10.1056/NEJMoa1013343 Google Scholar

References

Arber, DA. Acute myeloid leukemia. In: Elaine, SJ, Arber, DA, Campo, E, et al., eds. Hematopathology, 2nd ed. Philadelphia, PA: Elsevier; 2017:817–45.Google Scholar

Arber, DA, Brunning, RD, Orazi, A, et al. Acute myeloid leukaemia, not otherwise specified. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:156–66.Google Scholar

Puumala, SE, Ross, JA, Aplenc, R, et al. Epidemiology of childhood acute myeloid leukemia. Pediatr Blood Cancer. 2013;60:728–33.Google Scholar

Lorsbach, RB. Acute myeloid leukemia and related precursor neoplasms. In: Proytcheva, MA, ed. Diagnostic pediatric hematopathology. Cambridge, UK: Cambridge University Press; 2011:272–309.Google Scholar

Swerdlow, SH, Campo, E, Harris, NL, et al. Acute myeloid leukaemia and related precursor neoplasms. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon, France: IARC Press; 2008:109–47.Google Scholar

Swerdlow, SH, Campo, E, Harris, NL, et al. Acute myeloid leukaemia and related precursor neoplasms. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France; IARC Press; 2017:129–71.Google Scholar

Matynia, AP, Szankasi, P, Shen, W, et al. Molecular genetic biomarkers in myeloid malignancies. Arch Path Lab Med. 2015;139:594–601.Google Scholar

Arber, DA, Brunning, RD, Le Beau, MM, et al. Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:130–49.Google Scholar

Speck, NA, Gilliland, DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002;2:502–13.Google Scholar

Raimondi, SC, Chang, MN, Ravindranath, Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POC8821. Blood. 1999;94:3707–16.Google Scholar

Rubnitz, JE, Raimondi, SC, Halbert, AR, et al. Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution’s experience. Leukemia. 2002;16;2072–7.Google Scholar

Tallman, MS, Hakimian, D, Shaw, JM, et al. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol. 1993;11:690–7.Google Scholar

Johnson, RC, Savage, NM, Chiang, T, et al. Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2013;140:525–35.Google Scholar

Forestier, E and Schmiegelow, K. The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol. 2006;28:486–95.Google Scholar

Liu, P, Tarle, SA, Hajra, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science. 1993;261: 1041–4.Google Scholar

Gregory, J, Feusner, J. Acute promyelocytic leukemia in childhood. Curr Oncol Rep. 2009;11:439–45.Google Scholar

Zhou, Yi, Jorgensen, JL, Wang, SA, et al. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol. 2012;138:744–50.Google Scholar

Stein, E, Tallman, MS. Acute promyelocytic leukemia in children and adolescents. Acta Haematol. 2014;132:307–12.Google Scholar

Rubnitz, JE, Raimondi, SC, Tong, X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20:2302–9.Google Scholar

Elzamly, S, Chavali, S, Tonk, V, et al. Acute myeloid leukemia with KMT2A-SEPT5 translocation: A case report and review of the literature. SAGE Open Med Case Rep. 2018;6:1–5.Google Scholar

Shih, LY, Liang, DC, Fu, JF, et al. Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. Leukemia. 2006;20:218–23.Google Scholar

Sandahl, JD, Coenen, EA, Forestier, E, et al. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica. 2014;99:865–72.Google Scholar

Rogers, HJ, His, ED. Myeloid neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Surg Pathol. 2013;6:677–92.Google Scholar

Maseti, R, Guidi, V, Ronchini, L, et al. The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children. Crit Rev Oncol Hematol. 2019;138:132–8.Google Scholar

Bernstein, J, Dastugue, N, Haas, OA, et al. Nineteen cases of the t(1;22)(p13;q13) acute megakaryoblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group. Leukemia. 2000;14:216–8.Google Scholar

Coenen, EA, Zwaan, CM, Reinhardt, D, et al. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Münster AML-study group. Blood. 2013;122:2704–13.Google Scholar

Haferlach, T, Kohlmann, A, Klein, HU, et al. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia. 2009;23:934–43.Google Scholar

Dempsey, N, Khushmann, M, Hosein, P, et al. Acute myeloid leukemia with translocation (8;16)(p11;p13): a distinct syndrome – case report and literature review. Oncol Cancer Case Rep. 2017;3:2.Google Scholar

Braoudaki, M, Papathanassiou, C, Katsibardi, K, et al. The frequency of NPM1 mutations in childhood acute myeloid leukemia. J Hematol Oncol. 2010;3:41.Google Scholar

Falini, B, Martelli, MP, Bolli, N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006;108:1999–2005.Google Scholar

Kansal, R. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA. Hum Pathol. 2019;90:80–96.Google Scholar

Bacher, U, Schnittger, S, Macijewski, K, et al. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. Blood. 2012;119:4719–22.Google Scholar

Gaidzik, VI, Teleanu, V, Papaemmanuil, E. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016;30:2160–8.Google Scholar

Arber, DA, Brunning, RD, Orazi, A, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:150–2.Google Scholar

Koenig, KL, Sahasrabudhe, KD, Sigmund, AM, et al. AML with myelodysplasia-related changes: development, challenges, and treatment advances. Genes. 2020;11:845–57.Google Scholar

Arber, DA, Erba, HP. Diagnosis and treatment of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC). Am J Clin Pathol. 2020;154:731–41.Google Scholar

Vardiman, JW, Arber, DA, Brunning, RD, et al. Therapy-related myeloid neoplasms. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:153–5.Google Scholar

Wang, SA. Myelodysplastic syndromes and therapy-related myeloid neoplasms. In: Proytcheva, MA, ed. Diagnostic pediatric hematopathology. Cambridge, UK: Cambridge University Press; 2011:253–71.Google Scholar

Harada, H, Harada, Y, Tanaka, H, et al. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood. 2003;101:673–80.Google Scholar

Pileri, SA, Orazi, A, Faomo, B. Myeloid sarcoma. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:167–8.Google Scholar

Samborska, M, Derwich, K, Skalska-Sadowska, J, et al. Myeloid sarcoma in children – diagnostic and therapeutic difficulties. Contemp Oncol (Pozn). 2016;20:444–8.Google Scholar

Bhatnagar, N, Nizery, L, Tunstall, O, et al. Transient abnormal myelopoiesis and AML in Down syndrome: an update. Curr Hematol Malig Rep. 2016;11:333–41.Google Scholar

Arber, DA, Baumann, I, Niemeyer, CM, et al. Myeloid proliferations associated with Down syndrome. In: Swerdlow, SH, Campo, E, Harris, NL et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:169–71.Google Scholar

Gamis, AS, Alonzo, TA, Gerbing, RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood. 2011;118:6752–9.Google Scholar

Choi, JK. Hematologic abnormalities in individuals with Down syndrome. In: Proytcheva, MA, ed. Diagnostic pediatric hematopathology. Cambridge, UK: Cambridge University Press; 2011:310–22.Google Scholar

Roy, A, Cowan, G, Mead, AJ, et al. Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc Natl Acad Sci USA. 2012;109:17579–84.Google Scholar

Brink, DS. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome. Adv Anat Pathol. 2006;13:256–62.Google Scholar

References

Swerdlow, S, Campo, E, Harris, N, et al., eds. WHO classification of tumors of haematopoietic and lymphoid tissues. Rev. 4th ed. IARC Press; 2017.Google Scholar

Furutani, E, Shimamura, A. Genetic predisposition to MDS: diagnosis and management. Hematology Am Soc Hematol Educ Program. 2019;2019(1):110–9. doi: 10.1182/hematology.2019000021 Google Scholar

Kennedy, AL, Shimamura, A. Genetic predisposition to MDS: clinical features and clonal evolution. Blood. 2019;133(10):1071–85. doi: 10.1182/blood-2018-10-844662 Google Scholar

Smith, ML, Cavenagh, JD, Lister, TA, et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351(23):2403–7. doi: 10.1056/NEJMoa041331 Google Scholar

Polprasert, C, Schulze, I, Sekeres, MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27(5):658–70. doi: 10.1016/j.ccell.2015.03.017 Google Scholar

Lewinsohn, M, Brown, AL, Weinel, LM, et al. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood. 2016;127(8):1017–23. doi: 10.1182/blood-2015-10-676098 Google Scholar

Schlegelberger, B, Heller, PG. RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM). Semin Hematol. 2017;54(2):75–80. doi: 10.1053/j.seminhematol.2017.04.006 Google Scholar

Song, WJ, Sullivan, MG, Legare, RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23(2):166–75. doi: 10.1038/13793 Google Scholar

Walker, LC, Stevens, J, Campbell, H, et al. A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia. Br J Haematol. 2002;117(4):878–81. doi: 10.1046/j.1365-2141.2002.03512.x Google Scholar

Chisholm, KM, Denton, C, Keel, S, et al. Bone marrow morphology associated with germline. Pediatr Dev Pathol. 2019;22(4):315–28. doi: 10.1177/1093526618822108 Google Scholar

Marquez, R, Hantel, A, Lorenz, R, et al. A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma. 2014;55(12):2945–6. doi: 10.3109/10428194.2014.903476 Google Scholar

Di Paola, J, Porter, CC. ETV6-related thrombocytopenia and leukemia predisposition. Blood. 2019;134(8):663–7. doi: 10.1182/blood.2019852418 Google Scholar

Cioc, AM, Wagner, JE, MacMillan, ML, et al. Diagnosis of myelodysplastic syndrome among a cohort of 119 patients with Fanconi anemia: morphologic and cytogenetic characteristics. Am J Clin Pathol. 2010;133(1):92–100. doi: 10.1309/AJCP7W9VMJENZOVG Google Scholar

Cunniff, C, Bassetti, JA, Ellis, NA. Bloom’s syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition. Mol Syndromol.2017;8(1):4–23. doi: 10.1159/000452082 Google Scholar

Myers, KC, Furutani, E, Weller, E, et al. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. Lancet Haematol. 2020;7(3):e238–46. doi: 10.1016/S2352-3026(19)30206-6 Google Scholar

Simkins, A, Bannon, SA, Khoury, JD, et al. Diamond-Blackfan anemia predisposing to myelodysplastic syndrome in early adulthood. JCO Precis Oncol. 2017;1:1–5. doi: 10.1016/S2352-3026(19)30206-6 Google Scholar

Nagata, Y, Narumi, S, Guan, Y, et al. Germline loss-of-function. Blood. 2018;132(21):2309–13. doi: 10.1182/blood-2017-05-787390 Google Scholar

Ripperger, T, Schlegelberger, B. Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome. Eur J Med Genet. 2016;59(3):133–42. doi: 10.1016/j.ejmg.2015.12.014 Google Scholar

Kirwan, M, Walne, AJ, Plagnol, V, et al. Exome sequencing identifies autosomal-dominant SRP72 mutations associated with familial aplasia and myelodysplasia. Am J Hum Genet. 2012;90(5):888–92. doi: 10.1016/j.ajhg.2012.03.020 Google Scholar

Swaminathan, M, Bannon, SA, Routbort, M, et al. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019;5(1):a003210. doi: 10.1101/mcs.a003210 Google Scholar

Talwalkar, SS, Yin, CC, Naeem, RC, et al. Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome. Arch Pathol Lab Med. 2010;134(7):1010–5. doi: 10.5858/2009-0015-OA.1 Google Scholar

Shabanova, I, Cohen, E, Cada, M, et al. ERCC6L2-associated inherited bone marrow failure syndrome. Mol Genet Genomic Med. 2018;6(3):463–8. doi: 10.1002/mgg3.388 Google Scholar

Douglas, SPM, Siipola, P, Kovanen, PE, et al. ERCC6L2 defines a novel entity within inherited acute myeloid leukemia. Blood. 2019;133(25):2724–8. doi: 10.1182/blood-2019-01-896233 Google Scholar

Ripperger, T, Hofmann, W, Koch, JC, et al.MDS1 and EVI1 complex locus (MECOM): a novel candidate gene for hereditary hematological malignancies. Haematologica. 2018;103(2):e55–8. doi: 10.3324/haematol.2017.178723 Google Scholar

Rio-Machin, A, Vulliamy, T, Hug, N, et al. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nat Commun. 2020;11(1):1044. doi: 10.1038/s41467-020-14829-5 Google Scholar

References

Swerdlow, S, Campo, E, Harris, N, et al., eds. WHO classification of tumors of haematopoietic and lymphoid tissues. Rev. 4th ed. IARC Press; 2017.Google Scholar

Deng, W, Yang, M, Kuang, F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: a review of two cases. Mol Clin Oncol. 2017;7(4):709–15. doi: 10.3892/mco.2017.1370 Google Scholar

Li, Y, Sun, V, Sun, W, et al. Blastic plasmacytoid dendritic cell neoplasm in children. Hematol Oncol Clin North Am. 2020;34(3):601–12. doi: 10.1016/j.hoc.2020.01.008 Google Scholar

Jegalian, AG, Buxbaum, NP, Facchetti, F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873–9. doi: 10.3324/haematol.2010.026179 Google Scholar

Feuillard, J, Jacob, MC, Valensi, F, et al. Clinical and biologic features of CD4(+) CD56(+) malignancies. Blood. 2002;99(5):1556–63. doi:10.1182/blood.v99.5.1556 Google Scholar

Jacob, MC, Chaperot, L, Mossuz, P, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica. 2003;88(8):941–55.Google Scholar

Petrella, T, Bagot, M, Willemze, R, et al. Blastic NK-cell lymphomas (agranular CD4+ CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123(5):662–75.Google Scholar

Cota, C, Vale, E, Viana, I, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients.Am J Surg Pathol. 2010;34(1):75–87. doi:10.1097/PAS.0b013e3181c5e26b Google Scholar

Pilichowska, ME, Fleming, MD, Pinkus, JL, et al. CD4+/CD56+ hematodermic neoplasm (“blastic natural killer cell lymphoma”): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol. 2007;128(3):445–53. doi: 10.1309/W9Q5AGYDE5LANN39 Google Scholar

Urosevic, M, Conrad, C, Kamarashev, J, et al. CD4+ CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. Hum Pathol. 2005;36(9):1020–4. doi: 10.1016/j.humpath.2005.07.002 Google Scholar

Leroux, D, Mugneret, F, Callanan, M, et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique. Blood. 2002;99(11):4154–9. doi:10.1182/blood.v99.11.4154 Google Scholar

Sakamoto, K, Katayama, R, Asaka, R, et al. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia. 2018;32(12):2590–603. doi:10.1038/s41375-018-0154-5 Google Scholar

Tang, Z, Li, Y, Wang, W, et al. Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. Leuk Res. 2018;73:86–94. doi: 10.1038/s41375-018-0154-5 Google Scholar

Dijkman, R, van Doorn, R, Szuhai, K, et al. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood. 2007;109(4):1720–7. doi:10.1182/blood-2006-04-018143 Google Scholar

Sapienza, MR, Fuligni, F, Agostinelli, C, et al. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia. 2014;28(8):1606–16. doi: 10.1038/leu.2014.64 Google Scholar

Alayed, K, Patel, KP, Konoplev, S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88(12):1055–61. doi:10.1002/ajh.23567 Google Scholar

Suzuki, K, Suzuki, Y, Hama, A, et al. Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2017;31(7):1629–33. doi: 10.1038/leu.2017.101 Google Scholar

Ceribelli, M, Hou, ZE, Kelly, PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30(5):764–78. doi:10.1016/j.ccell.2016.10.002 Google Scholar

Jegalian, AG, Facchetti, F, Jaffe, ES. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol. 2009;16(6):392–404. doi: 10.1097/PAP.0b013e3181bb6bc2 Google Scholar

Roos-Weil, D, Dietrich, S, Boumendil, A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121(3):440–6. doi: 10.1182/blood-2012-08-448613 Google Scholar

Reimer, P, Rüdiger, T, Kraemer, D, et al. What is CD4+ CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637–46. doi: 10.1038/sj.bmt.1704215 Google Scholar

References

Borowitz, MJ, Bene, MC, Harris, NL, et al. Acute leukemias of ambiguous lineage. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Rev. 4th ed. Lyon, France:IARC Press; 2017:180–7.Google Scholar

Duffield, AS, Weir, EG, Borowitz, MJ. Acute leukemias of ambiguous lineage. In: Jaffe, ES, Arber, DA, Campo, E, et al., eds. Hematopathology. 2nd ed. Philadelphia, PA: Elsevier; 2017:775–82.Google Scholar

Aggarwal, N, Weinberg, OK. Update on acute leukemias of ambiguous lineage. Clin Lab Med. 2021;41:453–66.Google Scholar

Kurzer, JH, Weinberg, OK. Acute leukemias of ambiguous lineage: clarification on lineage specificity. Sur Pathol Clin. 2019;12:687–97.Google Scholar

Patel, SS, Weinberg, OK. Diagnostic workup of acute leukemias of ambiguous lineage. Am J Hematol. 2020;95:718–22.Google Scholar

Döhner, H, Estey, E, Grimwade, D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.Google Scholar

Weinberg, OK, Hasserjian, RP, Baraban, E, et al. Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019;32:1373–85.Google Scholar

Arber, DA, Brunning, RD, Orazi, A, et al. Acute myeloid leukemia, NOS. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Rev. 4th ed. Lyon, France: IARC Press; 2017:156–66.Google Scholar

Hanson, CA, Abaza, M, Sheldon, S, et al. Acute biphenotypic leukaemia: immunophenotypic and cytogenetic analysis.Br J Haematol. 1993;84:49–60.Google Scholar

Matutes, E, Morilla, R, Farahat, N, et al. Definition of acute biphenotypic leukemia. Haematologica. 1997;82:64–6.Google Scholar

Matutes, E, Pickl, WF, Van’t Veer, M, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 2011;117:3163–71.Google Scholar

Lau, LG, Tan, LK, Koay, ES, et al. Acute lymphoblastic leukemia with the phenotype of a putative B‐cell/T‐cell bipotential precursor. Am J Hematol. 2004;77:156–60.Google Scholar

Hirabayashi, S, Butler, ER, Ohki, K, et al. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: A retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Leukemia. 2021;10:1–6.Google Scholar

References

Onciu, M. Precursor lymphoid neoplasms. In: Proytcheva, MA, ed. Diagnostic pediatric hematopathology. Cambridge, UK: Cambridge University Press; 2011:323–44.Google Scholar

Borowitz, MJ, Chan, JKC, Downing, JR, et al. B-lymphoblastic leukaemia/lymphoma, not otherwise specified. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:200–2.Google Scholar

Borowitz, MJ, Chan, JKC, Bene, MC, et al. T-lymphoblastic leukaemia/lymphoma. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:209–13.Google Scholar

Duffield, AS, Racke, FK, Borowitz, MJ. Precursor B- and T-cell neoplasms. In: Jaffe, ES, Arber, DA, Campo, E, et al., eds. Hematopathology, 2nd ed. Philadelphia, PA: Elsevier;2017:761–73.Google Scholar

Borowitz, MJ, Chan, JKC, Downing, JR, et al. B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed.Lyon, France: IARC Press; 2017:203–9.Google Scholar

Bennett, JM, Catovaky, D, Daniel, MT et al. Proposals for the classification of the acute leukaemia. Br. J. Haematol. 1976; 33:451–8.Google Scholar

Malard, F, Mohty, M. Acute lymphoblastic leukaemia. Lancet. 2020. 395:1146–62.Google Scholar

Inaba, H, Mullighan, CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524–39.Google Scholar

Holmfeldt, L, Wei, L, Diaz-Flores, E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45:242–52.Google Scholar

Moriyama, T, Metzger, ML, Wu, G, et al. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol. 2015;16:1659–66.Google Scholar

Shah, S, Schrader, KA, Waanders, E, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013;45:1226–31.Google Scholar

Noetzli, L, Lo, RW, Lee-Sherick, AB, et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015;47:535–8.Google Scholar

Knez, V, Liu, X, Schowinsky, J, et al. Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: A multi-institutional study. Leuk Lymphoma. 2019;60:1006–13.Google Scholar

Valbuena, JR, Medeiros, LJ, Rassidakis, GZ, et al. Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2006;126:235–40.Google Scholar

Hashimoto, M, Yamashita, Y, Mori, N. Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol. 2002;197:341–7.Google Scholar

Gohring, G, Michalva, K, Beverloo, B, et al. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood. 2010;116:3766–9.Google Scholar

Knez, V, Bao, L, Carstens, B, et al. Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood. Leuk Lymphoma. 2020;61:2129–35.Google Scholar

Ramakers-van Woerden, NL, Pieters, R, Loonen, AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96:1094–9.Google Scholar

Nachman, JB, Heerema, NA, Sather, H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007;110:1112–5.Google Scholar

Den Boer, ML, van Slegtenhorst, M, De Menezes, RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125–34.Google Scholar

Yadav, V, Ganesan, P, Veeramani, R, et al. Philadelphia-like acute lymphoblastic leukemia: a systematic review. Clin Lymphoma Myeloma Leuk. 2021;21:e57–e65.Google Scholar

Wenzinger, C, Williams, E, Gru, AA. Updates in the pathology of precursor lymphoid neoplasms in the revised fourth edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Curr Hematol Malig Rep. 2018;13:275–88.Google Scholar

Khan, M, Siddiqi, R, Tran, TH. Philadelphia chromosome-like acute lymphoblastic leukemia: a review of the genetic basis, clinical features, and therapeutic options. Semi Hematol. 2018;55:235–41.Google Scholar

Loh, ML, Zhang, J, Harvey, RC, et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children’s Oncology Group TARGET Project. Blood. 2013;121:485–8.Google Scholar

Lyapichev, KA, Sukswai, N, Angelova, E, et al. CD123 expression in Philadelphia chromosome-like B acute lymphoblastic leukemia/lymphoma. Clin Lymphoma Myeloma Leuk. 2021;21:e317–e20.Google Scholar

Sadras, T, Heatley, SL, Kok, CH, et al. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Lett. 2017;408:92–101.Google Scholar

Yap, KL, Furtado, LV, Kiyotani, K, et al. Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2017;58:950–8.Google Scholar

Harrison, CJ. Blood spotlight on iAMP21 acute lymphoblastic leukemia (ALL), a high-risk pediatric disease. Blood. 2015;125:1383–6.Google Scholar

Lilljebjorn, H, Henningsson, R, Hyrenius-Wittsten, A, et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun. 2016;7:11790.Google Scholar

Zhang, J, McCastlain, K, Yoshihara, H, et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016;48:1481–9.Google Scholar

Dib, C, Zakharova, V, Popova, E, et al. DUX4 pathological expression: causes and consequences in cancer. Trends Cancer. 2019;5:268–71.Google Scholar

Tian, L, Shao, Y, Nance, S, et al. Long-read sequencing unveils IGH-DUX4 translocation into the silenced IGH allele in B-cell acute lymphoblastic leukemia. Nat Commun. 2019;10:2789.Google Scholar

Tanaka, Y, Kawazu, M, Yasuda, T, et al. Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia. Haematologica. 2018;103:e522–e6.Google Scholar

Rehn, JA, O’Connor, MJ, White, DL, et al. DUX hunting – clinical features and diagnostic challenges associated with DUX4-Rearranged leukaemia. Cancers (Basel). 2020;12.Google Scholar

Schinnerl, D, Mejstrikova, E, Schumich, A, et al. CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia. Haematologica. 2019;104:e352–e5.Google Scholar

Novakova, M, Zaliova, M, Fiser, K, et al. DUX4 r, ZNF384 r and PAX5-P80 R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch. Haematologica. 2021;106:2066–75.Google Scholar

Ueno, H, Yoshida, K, Shiozawa, Y, et al. The prognostic value of TP53 mutations depends on clinical backgrounds in pediatric patients with acute lymphoblastic leukemia. Blood. 2018;132 (Suppl 1):4077.Google Scholar

Kurtin, P. Thymus gland. In: Collins, RD, Swerdlow, SH, eds. Pediatric hematopathology. Philadelphia, PA: Churchill Livingstone; 2001:323–41.Google Scholar

Borowitz, MJ, Bene, MC, Harris, NL, et al. NK-lymphoblastic leukaemia/lymphoma. In: Swerdlow, SH, Campo, E, Harris, NL, et al., eds. WHO classification of tumours of haematopoietic and lymphoid tissues, rev. 4th ed. Lyon, France: IARC Press; 2017:213.Google Scholar

References

Proytcheva, MA. Pediatric small blue cell tumors metastatic to the bone marrow. In: Proytcheva, MA, eds. Diagnostic pediatric hematopathology. Cambridge: UK: Cambridge University Press; 2011:379–94.Google Scholar

Kopp, LM, Hu, C, Rozo, B, et al. Utility of bone marrow aspiration and biopsy in initial staging of Ewing sarcoma. Pediatr Blood Cancer. 2015;62:12–5.Google Scholar

Parsons, LN, Gheorghe, G, Yan, K, et al. An evidence-based recommendation for a standardized approach to detecting metastatic neuroblastoma in staging bone marrow biopsies. Pediatr Dev Pathol. 2017;20:38–43.Google Scholar

Bailey, KA, Wexier, LH. Pediatric rhabdomyosarcoma with bone marrow metastasis. Pediatr Blood Cancer. 2020;67(5):e28219.Google Scholar

Cesari, M, Righi, A, Colangeli, M, et al. Bone marrow biopsy in the initial staging of Ewing sarcoma: Experience from a single institution. Pediatr Blood Cancer. 2019;66(6):e27653.Google Scholar

Kontny, U, Franzen, S, Behrends, U, et al. Diagnosis and treatment of nasopharyngeal carcinoma in children and adolescents – recommendations of the GPOH-NPC Study Group. Klin Padiatr. 2016;228:105–12.Google Scholar

Book contents

Section IV - Neoplastic Disorders of Bone Marrow

Access options

References

References

References

References

References

References

References

References

References

References

References

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive